GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Piotroski F-Score

TELA Bio (TELA Bio) Piotroski F-Score : 5 (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TELA Bio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for TELA Bio's Piotroski F-Score or its related term are showing as below:

TELA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 5
Current: 5

During the past 7 years, the highest Piotroski F-Score of TELA Bio was 5. The lowest was 3. And the median was 5.


TELA Bio Piotroski F-Score Historical Data

The historical data trend for TELA Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Piotroski F-Score Chart

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A 5.00 4.00 3.00 5.00

TELA Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 5.00 6.00 5.00

Competitive Comparison of TELA Bio's Piotroski F-Score

For the Medical Devices subindustry, TELA Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TELA Bio's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where TELA Bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -12.027 + -10.79 + -10.957 + -12.89 = $-46.66 Mil.
Cash Flow from Operations was -11.574 + -11.264 + -6.968 + -11.051 = $-40.86 Mil.
Revenue was 11.909 + 14.494 + 15.052 + 16.998 = $58.45 Mil.
Gross Profit was 7.898 + 10.201 + 10.389 + 11.624 = $40.11 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(67.855 + 58.788 + 94.386 + 87.317 + 78.048) / 5 = $77.2788 Mil.
Total Assets at the begining of this year (Dec22) was $67.86 Mil.
Long-Term Debt & Capital Lease Obligation was $40.52 Mil.
Total Current Assets was $71.73 Mil.
Total Current Liabilities was $16.97 Mil.
Net Income was -10.862 + -12.741 + -10.714 + -9.979 = $-44.30 Mil.

Revenue was 8.231 + 10.406 + 11.159 + 11.622 = $41.42 Mil.
Gross Profit was 4.999 + 6.55 + 7.319 + 8.176 = $27.04 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(62.544 + 55.355 + 51.333 + 79.563 + 67.855) / 5 = $63.33 Mil.
Total Assets at the begining of last year (Dec21) was $62.54 Mil.
Long-Term Debt & Capital Lease Obligation was $39.92 Mil.
Total Current Assets was $62.45 Mil.
Total Current Liabilities was $12.40 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TELA Bio's current Net Income (TTM) was -46.66. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

TELA Bio's current Cash Flow from Operations (TTM) was -40.86. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-46.664/67.855
=-0.68770172

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-44.296/62.544
=-0.7082374

TELA Bio's return on assets of this year was -0.68770172. TELA Bio's return on assets of last year was -0.7082374. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

TELA Bio's current Net Income (TTM) was -46.66. TELA Bio's current Cash Flow from Operations (TTM) was -40.86. ==> -40.86 > -46.66 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=40.515/77.2788
=0.52427056

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=39.916/63.33
=0.6302858

TELA Bio's gearing of this year was 0.52427056. TELA Bio's gearing of last year was 0.6302858. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=71.726/16.967
=4.22738257

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=62.447/12.403
=5.03483028

TELA Bio's current ratio of this year was 4.22738257. TELA Bio's current ratio of last year was 5.03483028. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

TELA Bio's number of shares in issue this year was 24.508. TELA Bio's number of shares in issue last year was 19.191. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=40.112/58.453
=0.68622654

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=27.044/41.418
=0.65295282

TELA Bio's gross margin of this year was 0.68622654. TELA Bio's gross margin of last year was 0.65295282. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=58.453/67.855
=0.86143983

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=41.418/62.544
=0.6622218

TELA Bio's asset turnover of this year was 0.86143983. TELA Bio's asset turnover of last year was 0.6622218. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

TELA Bio has an F-score of 5 indicating the company's financial situation is typical for a stable company.

TELA Bio  (NAS:TELA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TELA Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of TELA Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TELA Bio (TELA Bio) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Executives
Gregory A. Firestone officer: Chief Business Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca officer: COO and CFO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish director, officer: Chief Executive Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p. other: See footnotes 1 and 2 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp 10 percent owner QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p. 10 percent owner CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran director 0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans director 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355